Jason Lettmann is a General Partner of Lightstone Ventures and focuses on investments in the biopharmaceutical and medical technology sectors. Jason brings 20 years of operating and venture experience in the life sciences and also is a General Partner at Morgenthaler Ventures. He currently serves on the Board of Directors of ALX Oncology (NASDAQ: ALXO), Atsena Therapeutics, Carrick Therapeutics, Cerevance, FIRE1, Relievant Medsystems, and Second Genome. Jason led the firm’s investments and served as a Director of Ra Pharmaceuticals (acquired by UCB) and Vapotherm (NASDAQ: VAPO). Jason also served as the interim CEO of Promedior and led the company through its sale to Roche in 2020. In 2014, Jason established Lightstone’s Europe office located in Dublin, Ireland, to expand the firm’s investment activities to Europe and currently serves as Director of Lightstone Capital Management Ireland Ltd.
Before joining Morgenthaler in 2009, Jason was a Vice President at Split Rock Partners where he focused on early-stage investments in the life sciences. During his time at Split Rock, Jason was actively involved with the firm’s investment in Ardian (acquired by Medtronic), Cabochon Aesthetics (acquired by Ulthera), Atritech (acquired by Boston Scientific), Entellus Medical (acquired by Stryker), Evalve (acquired by Abbott), and Transcend Medical (acquired by Alcon). Jason was also previously a co-founder and on the Board of Tarsus Medical before its acquisition by Integra Life Sciences in 2013.
Prior to venture, Jason’s experience includes tenure with Guidant’s Compass Group which focused on corporate venture investing and business development, as well as a consultant with Accenture’s Health and Life Science practice, where he advised clients across the medical device, pharmaceutical, and healthcare payer sectors. Jason also previously worked as a Genetic Research Analyst at the University of Iowa Hospitals and Clinics.All Speakers